E2025 / Eisai - LARVOL DELTA

Drug Development. (PubMed, Alzheimers Dement) - "SILK technology demonstrated that E2025 increased the turnover rate of EphA4 in a concentration-dependent manner. Therefore, this method may be applicable for assessing the pharmacodynamic effects of E2025. References [1] Verma, M., Chopra, M. & Kumar, H. Cell Mol Neurobiol 43, 3375-3391, (2023). [2] Vargas, L. M., Cerpa, W., Munoz, F. J., Zanlungo, S. & Alvarez, A. R. Biochim Biophys Acta Mol Basis Dis 1864, 1148-1159, (2018)."

Journal • Alzheimer's Disease • CNS Disorders • EPHA4

Developing Topics. (PubMed, Alzheimers Dement) - "E2025 specifically suppresses the EphA4 pathway via multiple modes of action, and suppresses progression of tau pathology in a transgenic tau model of AD."

Journal • Alzheimer's Disease • CNS Disorders • EPHA4

E2025, a novel anti-EphA4 antibody, enhances EphA4 cleavage, and suppresses tau pathologies in a transgenic model of AD (AAIC 2024) - "E2025 specifically suppresses the EphA4 pathway via multiple modes of action, and suppresses progression of tau pathology in a transgenic tau model of AD."

Alzheimer's Disease • CNS Disorders • EPHA4

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of E2025 in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Eisai Inc. | Recruiting ➔ Completed

Trial completion

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of E2025 in Healthy Participants (clinicaltrials.gov) - P1 | N=41 | Recruiting | Sponsor: Eisai Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of E2025 in Healthy Participants (clinicaltrials.gov) - P1 | N=41 | Not yet recruiting | Sponsor: Eisai Inc.

New P1 trial